Cargando…

Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer

PURPOSE: We conducted a phase I trial of BNP7787 (disodium 2,2′-dithio-bis-ethane sulfonate, Tavocept™), a novel chemoprotective and antitumor enhancing agent administered in combination with paclitaxel and cisplatin. The primary aim was to determine a safe and potentially efficacious BNP7787 dose f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Masuda, Noriyuki, Negoro, Shunichi, Hausheer, Frederick, Nakagawa, Kazuhiko, Matsui, Kaoru, Kudoh, Shinzoh, Takeda, Koji, Yamamoto, Nobuyuki, Yoshimura, Naruo, Ohashi, Yasuo, Fukuoka, Masahiro
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2010
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3043260/ https://www.ncbi.nlm.nih.gov/pubmed/20473611 http://dx.doi.org/10.1007/s00280-010-1340-y

Ejemplares similares

Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule
por: Boven, E, et al.
Publicado: (2005)

Cysteine Specific Targeting of the Functionally Distinct Peroxiredoxin and Glutaredoxin Proteins by the Investigational Disulfide BNP7787
por: Parker, Aulma R., et al.
Publicado: (2015)

Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats
por: Verschraagen, M, et al.
Publicado: (2004)

Enhanced Antitumor Efficacy of a Combination of CPT‐11, a New Derivative of Camptothecin, and Cisplatin against Human Lung Tumor Xenografts
por: Kudoh, Shinzoh, et al.
Publicado: (1993)

Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787
por: Parker, Aulma R, et al.
Publicado: (2015)

Relationship between the Pharmacokinetics of Irinotecan and Diarrhea during Combination Chemotherapy with Cisplatin
por: Kudoh, Shinzoh, et al.
Publicado: (1995)

Determinants of Myelosuppression in the Treatment of Non‐small Cell Lung Cancer with Cisplatin‐containing Chemotherapy
por: Matsui, Kaoru, et al.
Publicado: (1996)

A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B(12) in Japanese patients with solid tumours
por: Nakagawa, K, et al.
Publicado: (2006)

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer
por: Negoro, S, et al.
Publicado: (2003)

Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer
por: Takeda, K, et al.
Publicado: (1999)

Combining anti-CTLA4 with RG7787, an immunotoxin targeting mesothelin, promotes tumor eradication
por: Leshem, Jasmin, et al.
Publicado: (2015)

Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study
por: Oka, Takako, et al.
Publicado: (2014)

Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes
por: Kolyvas, Emily, et al.
Publicado: (2016)

Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer
por: Yamada, M, et al.
Publicado: (2002)

Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer.
por: Matsui, K., et al.
Publicado: (1998)

Direct Immunochemiluminescent Assay for proBNP and Total BNP in Human Plasma proBNP and Total BNP Levels in Normal and Heart Failure
por: Nishikimi, Toshio, et al.
Publicado: (2013)

Plasma RANTES, IL-10, and IL-8 levels in non–small-cell lung cancer patients treated with EGFR-TKIs
por: Umekawa, Kanako, et al.
Publicado: (2013)

Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer
por: Suzumura, Tomohiro, et al.
Publicado: (2012)

C609T Polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin
por: Nagata, Misato, et al.
Publicado: (2013)

Review of the Management of Relapsed Small-Cell Lung Cancer with Amrubicin Hydrochloride
por: Kimura, Tatsuo, et al.
Publicado: (2011)

CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.
por: Fukuoka, M., et al.
Publicado: (1997)

Studies with 1,2-dithiole-3-thione as a chemoprotector of hydroquinone-induced toxicity to DBA/2-derived bone marrow stromal cells.
por: Twerdok, L E, et al.
Publicado: (1993)

Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.
por: Masuda, N., et al.
Publicado: (1993)

Interleukin 6 is a cause of flu-like symptoms in treatment with a deoxycytidine analogue.
por: Masuda, N., et al.
Publicado: (1998)

Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
por: Ota, Takayo, et al.
Publicado: (2019)

Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803)
por: Yamamoto, N, et al.
Publicado: (2004)

Enhancement of Tumor Radio‐response by Irinotecan in Human Lung Tumor Xenografts
por: Tamura, Kenji, et al.
Publicado: (1997)

Topical Curcumin as Chemoprotector Against Photoproducts Production: The Role of Cyclobutyl Pyrimidine Dimers, 8-Hydroxy2ʹDeoxyguanosine Expression and Epidermal Hyperplasia in Acute and Chronic UVB-Induced Mice
por: Djawad, Khairuddin, et al.
Publicado: (2022)

B-Type Natriuretic Peptide (BNP) Revisited—Is BNP Still a Biomarker for Heart Failure in the Angiotensin Receptor/Neprilysin Inhibitor Era?
por: Nishikimi, Toshio, et al.
Publicado: (2022)

Die Biomarker BNP und NT‑proBNP
por: Oremek, G. M., et al.
Publicado: (2023)

Agreement of BNP and NT-proBNP and the influence of clinical and laboratory variables
por: Curiati, Milena Novaes Cardoso, et al.
Publicado: (2013)

A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group.
por: Masuda, N., et al.
Publicado: (1998)

ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with EGFR mutation‐positive non‐small‐cell lung cancer
por: Azuma, Koichi, et al.
Publicado: (2018)

Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure
por: Palazzuoli, A, et al.
Publicado: (2010)

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
por: Tamura, K, et al.
Publicado: (2008)

BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing?
por: Lewis, Robert A., et al.
Publicado: (2020)

New Era for Next-Generation Sequencing in Japan
por: Takeda, Masayuki, et al.
Publicado: (2019)

BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in Both Clinical and Forensic Medicine
por: Cao, Zhipeng, et al.
Publicado: (2019)

Towards Point-of-Care Heart Failure Diagnostic Platforms: BNP and NT-proBNP Biosensors
por: Alawieh, Hussein, et al.
Publicado: (2019)

Effect of Synthetic Truncated Apolipoprotein C-I Peptide on Plasma Lipoprotein Cholesterol in Nonhuman Primates
por: Kushwaha, Rampratap S., et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_s8bvo7rao0tk2t0elkhd4qn4hj